source
- AbbVie and BMS each secure FDA approval, but impact of their neuro‑drug acquisitions remains uncertainAbbVie and Bristol Myers Squibb have both received FDA clearance for new Parkinson's treatments, prompting a fresh look at the large neuro‑focused deals they completed last year. AbbVie bought Cere…
- FDA launches Rare Disease Framework to embed patient input early in drug developmentFDA's Center for Biologics Research and Evaluation (CBER) director Karim Mikhail announced a new Rare Disease Framework Initiative aimed at moving patient perspectives from an optional, late‑stage…